These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24398603)

  • 1. Gene-modified hematopoietic stem cells for cancer immunotherapy.
    Larson S; De Oliveira SN
    Hum Vaccin Immunother; 2014; 10(4):982-5. PubMed ID: 24398603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stem cells for cancer immunotherapy.
    Gschweng E; De Oliveira S; Kohn DB
    Immunol Rev; 2014 Jan; 257(1):237-49. PubMed ID: 24329801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.
    Kao RL; Truscott LC; Chiou TT; Tsai W; Wu AM; De Oliveira SN
    Hum Gene Ther; 2019 Apr; 30(4):413-428. PubMed ID: 30860401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.
    Crowther MD; Svane IM; Met Ö
    Cells; 2020 Jun; 9(7):. PubMed ID: 32630096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.
    De Oliveira SN; Ryan C; Giannoni F; Hardee CL; Tremcinska I; Katebian B; Wherley J; Sahaghian A; Tu A; Grogan T; Elashoff D; Cooper LJ; Hollis RP; Kohn DB
    Hum Gene Ther; 2013 Oct; 24(10):824-39. PubMed ID: 23978226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.
    Gschweng EH; McCracken MN; Kaufman ML; Ho M; Hollis RP; Wang X; Saini N; Koya RC; Chodon T; Ribas A; Witte ON; Kohn DB
    Cancer Res; 2014 Sep; 74(18):5173-83. PubMed ID: 25038231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic Stem Cell Approaches to Cancer.
    Adair JE; Kubek SP; Kiem HP
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):897-912. PubMed ID: 28895855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
    Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
    Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise and potential pitfalls of chimeric antigen receptors.
    Sadelain M; Brentjens R; Rivière I
    Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptors for stem cell based immunotherapy.
    Badowski MS; Zhang T; Tsang TC; Harris DT
    J Exp Ther Oncol; 2009; 8(1):53-63. PubMed ID: 19827271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
    Hu Y; Tian ZG; Zhang C
    Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designer T-cells and T-cell receptors for customized cancer immunotherapies.
    Legut M; Sewell AK
    Curr Opin Pharmacol; 2018 Aug; 41():96-103. PubMed ID: 29852403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer T cell immunotherapy with bispecific antibodies and chimeric antigen receptors.
    Lacher MD; Provenzano M
    Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):239-54. PubMed ID: 23688207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance.
    Wellhausen N; Baek J; Gill SI; June CH
    Nat Rev Cancer; 2024 Sep; 24(9):614-628. PubMed ID: 39048767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.